Investigation of ANO7 Gene and Prostate Cancer Risk

Overview of the Study

Recent research has focused on the ANO7 gene, which may play a significant role in the diagnosis of prostate cancer. While numerous genes have been linked to prostate cancer, few have been directly associated with the severity and survivability of the disease. A deeper understanding of the genetic factors that influence prostate cancer risk could enhance diagnosis, treatment, and preventive strategies.

Study Details

A European study published in the *International Journal of Cancer* examined the correlation between various forms of the ANO7 gene and the risk of developing prostate cancer. ANO7 was selected for this study due to its genomic location linked to prostate cancer risk, its specific activity within the prostate gland, and the association of low ANO7 activity with high-grade and metastatic prostate cancer.

Sample Population

The researchers analyzed DNA from blood and tissue samples of 1,769 prostate cancer patients from Finland, Sweden, and Ireland. For comparative purposes, DNA from blood samples of 1,711 men without prostate cancer was also obtained.

Forms of ANO7 Analyzed

Among the 215 identified forms of the ANO7 gene, three were selected for further examination based on their rarity and notable effects on ANO7 protein production:
– **Form 1 (rs148609049)**: Present in 2% of patient blood samples.
– **Form 2 (rs77559646)**: Found in 8% of patient blood samples and 9% of castration-resistant tumor samples.
– **Form 3 (rs181722382)**: Detected in 4% of patient blood samples and 18% of castration-resistant tumor samples.

None of these forms were identified in the control group.

Correlation with Family History and Survival Rates

Forms 1 and 2 were more prevalent among individuals with a strong family history of prostate cancer. Patients with Form 1 exhibited a 76% increased likelihood of mortality due to prostate cancer compared to those with alternative forms. Form 2 was more common in patients than in controls and was also associated with aggressive cases of prostate cancer. Additionally, high ANO7 activity in tumors was linked to lower overall survival rates.

Implications of the Findings

The results indicate that the ANO7 gene may serve as a marker for prostate cancer risk, with different forms affecting both the likelihood of developing the disease and its aggressiveness. Screening for Forms 1 and 2 could potentially aid in diagnosing and prognosticating prostate cancer. Specifically, rs148609049 may assist in evaluating overall survivability, while rs77559646 could be useful in assessing disease aggressiveness.

Contradictions and Future Research

Contrary to previous studies, high ANO7 activity was found to be associated with more aggressive forms of prostate cancer. Further research is necessary to confirm these findings and to explore whether this association is characteristic of ANO7-related prostate cancer.

Limitations of the Study

This study’s population consisted exclusively of Caucasian Northern Europeans, which may limit the generalizability of the findings to other populations. Additionally, the assessment of survival focused solely on tumor ANO7 activity and did not consider the activity in non-cancerous tissue.

Conclusion

Research into the ANO7 gene appears to offer promising avenues for developing new diagnostic methods for prostate cancer.

Written by

Raishard Haynes, MBS

Reference

Kaikkonen, E. et al. (2018). ANO7 is associated with aggressive prostate cancer. *Int J Cancer*. doi: 10.1002/ijc.31746